Workshop
Selecting an appropriate first-in-human (FIH) dose is a pivotal step in successfully translating innovative therapeutic modalities such as antibody-drug conjugates (ADCs), bispecific antibodies, fusion proteins, gene therapies, antisense oligonucleotides (ASOs) and combination treatments into clinical development.
Traditional dose selection approaches often fall short in addressing the unique pharmacokinetic (PK) and pharmacodynamic (PD) characteristics of these modalities, increasing the risk of suboptimal efficacy or safety concerns.
Join us at the Antibody Industrial Symposium in Montpellier (France) on 30th June for a one-hour workshop focused on practical, model-informed strategies to optimize FIH dose selection.
Designed for scientists and decision-makers in preclinical and translational research, this session will offer a clear, strategic framework for using PK/PD modeling to inform FIH study design. Whether you are working on preclinical development, translational strategy, or regulatory interactions, you will leave with actionable insights to enhance decision-making in early-phase drug development.
Don’t miss this opportunity to sharpen your strategy and stay current with best practices in model-informed drug development.